Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.

Saved in:
Bibliographic Details
Title: Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.
Authors: Wall MA; Institute for Systems Biology, Seattle, WA, USA., Turkarslan S; Institute for Systems Biology, Seattle, WA, USA., Wu WJ; Institute for Systems Biology, Seattle, WA, USA., Danziger SA; Bristol-Myers Squibb, Summit, NJ, USA., Reiss DJ; Bristol-Myers Squibb, Summit, NJ, USA., Mason MJ; Sage Bionetworks, Seattle, WA, USA., Dervan AP; Bristol-Myers Squibb, Summit, NJ, USA., Trotter MWB; Celgene Institute for Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Summit, NJ, USA., Bassett D; Bristol-Myers Squibb, Summit, NJ, USA., Hershberg RM; Celgene Corporation, Seattle, WA, USA., Lomana ALG; Institute for Systems Biology, Seattle, WA, USA. adrian.lopezgarciadelomana@isbscience.org., Ratushny AV; Bristol-Myers Squibb, Summit, NJ, USA. alexander.ratushnyy@bms.com., Baliga NS; Institute for Systems Biology, Seattle, WA, USA. nitin.baliga@isbscience.org.; Departments of Biology, Microbiology, and Molecular Engineering Sciences, University of Washington, Seattle, WA, USA. nitin.baliga@isbscience.org.; Lawrence Berkeley National Labs, Berkeley, CA, USA. nitin.baliga@isbscience.org.
Source: NPJ precision oncology [NPJ Precis Oncol] 2021 Jun 28; Vol. 5 (1), pp. 60. Date of Electronic Publication: 2021 Jun 28.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2397-768X
DOI:10.1038/s41698-021-00185-0